Chinese Academy of Sciences
Clinical Trials
61
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (48 trials with phase data)• Click on a phase to view related trials
Protein Supplementation Intervention on Body Weight
- Conditions
- ObesityWeight LossProtein Supplementation
- Interventions
- Behavioral: Calorie-restricted balanced dietBehavioral: General lifestyle and nutritional educationDietary Supplement: Dietary protein supplementation
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT06989203
- Locations
- 🇨🇳
Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
Probiotic Intervention on Body Weight
- Conditions
- ObesityHomeostasisWeight LossProbiotic Intervention
- Interventions
- Behavioral: Energy-restricted nutritional and lifestyle interventionBehavioral: General lifestyle and nutritional educationDietary Supplement: PlaceboDietary Supplement: Probiotic
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 140
- Registration Number
- NCT06989177
- Locations
- 🇨🇳
Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
- Conditions
- Gastric CancerImagePathology
- Interventions
- Drug: Neoadjuvant Chemotherapy
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT06035250
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
🇨🇳Peking University Cancer Hospital & Institute, Beijing, China
Quality Control of Ultrasound Images During Early Pregnancy Via AI
- Conditions
- Early Pregnancy
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT06002412
- Locations
- 🇨🇳
Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Changsha Hospital for Maternal and Child Health Care, Changsha, China
Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models
- Conditions
- Gastrointestinal Neoplasm Malignant
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 400
- Registration Number
- NCT06002425
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇨🇳Jiangmen Central Hospital, Jiangmen, Guangdong, China
🇨🇳The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 13
- Next
News
Novel Bispecific Antibody Shows Promise for Autoimmune Disease Treatment in Preclinical Studies
Researchers at NYU Langone Health developed a bispecific antibody called BiTS that targets both T cell receptors and LAG-3 checkpoints to selectively suppress autoimmune T cells.
China's Aphranel MagiCCrystal CaHA Filler Receives Global Regulatory Approvals, Setting New Standards in Regenerative Aesthetics
Aphranel MagiCCrystal, developed by Shanghai Moyom Biotechnology, has become China's first Class III calcium hydroxylapatite (CaHA) microsphere-based dermal filler to receive NMPA certification.
Novel Digital Cognitive Training Shows Promise for Coronary Heart Disease Patients in Clinical Trial
A groundbreaking clinical trial is evaluating a cloud-based cognitive training app for coronary heart disease patients, featuring adaptive algorithms and classic psychological paradigms.
Oncolytic Virus Ad-TD-nsIL12 Shows Promise in Glioblastoma Phase I Trial
A Phase I trial of Ad-TD-nsIL12, an oncolytic virus, demonstrated safety and efficacy in recurrent glioblastoma patients.